BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pérez de Vega MJ, Ferrer-montiel A, González-muñiz R. Recent progress in non-opioid analgesic peptides. Archives of Biochemistry and Biophysics 2018;660:36-52. [DOI: 10.1016/j.abb.2018.10.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Tétreault P, Besserer-offroy É, Brouillette RL, René A, Murza A, Fanelli R, Kirby K, Parent AJ, Dubuc I, Beaudet N, Côté J, Longpré J, Martinez J, Cavelier F, Sarret P. Pain relief devoid of opioid side effects following central action of a silylated neurotensin analog. European Journal of Pharmacology 2020;882:173174. [DOI: 10.1016/j.ejphar.2020.173174] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
2 Jergova S, Perez C, Imperial JS, Gajavelli S, Jain A, Abin A, Olivera BM, Sagen J. Cannabinoid receptor agonists from Conus venoms alleviate pain-related behavior in rats. Pharmacol Biochem Behav 2021;205:173182. [PMID: 33774007 DOI: 10.1016/j.pbb.2021.173182] [Reference Citation Analysis]
3 Webster CG, Park H, Ennis AF, Hong J. Synthetic efforts toward the bicyclo[3.2.1]octane fragment of rhodojaponin III. Tetrahedron Lett 2021;71:153055. [PMID: 34054153 DOI: 10.1016/j.tetlet.2021.153055] [Reference Citation Analysis]
4 Butrón D, Zamora-Carreras H, Devesa I, Treviño MA, Abian O, Velázquez-Campoy A, Bonache MÁ, Lagartera L, Martín-Martínez M, González-Rodríguez S, Baamonde A, Fernández-Carvajal A, Ferrer-Montiel A, Jiménez MÁ, González-Muñiz R. DD04107-Derived neuronal exocytosis inhibitor peptides: Evidences for synaptotagmin-1 as a putative target. Bioorg Chem 2021;115:105231. [PMID: 34388485 DOI: 10.1016/j.bioorg.2021.105231] [Reference Citation Analysis]
5 Vivancos M, Fanelli R, Besserer-Offroy É, Beaulieu S, Chartier M, Resua-Rojas M, Mona CE, Previti S, Rémond E, Longpré JM, Cavelier F, Sarret P. Metabolically stable neurotensin analogs exert potent and long-acting analgesia without hypothermia. Behav Brain Res 2021;405:113189. [PMID: 33607165 DOI: 10.1016/j.bbr.2021.113189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Tsagareli MG, Nozadze I. An overview on transient receptor potential channels superfamily. Behav Pharmacol 2020;31:413-34. [PMID: 31833970 DOI: 10.1097/FBP.0000000000000524] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
7 Gormley M, Oliverio O, Kapidzic M, Ona K, Hall S, Fisher SJ. RNA profiling of laser microdissected human trophoblast subtypes at mid-gestation reveals a role for cannabinoid signaling in invasion. Development 2021;148:dev199626. [PMID: 34557907 DOI: 10.1242/dev.199626] [Reference Citation Analysis]
8 Chartier M, Desgagné M, Sousbie M, Côté J, Longpré JM, Marsault E, Sarret P. Design, Structural Optimization, and Characterization of the First Selective Macrocyclic Neurotensin Receptor Type 2 Non-opioid Analgesic. J Med Chem 2021;64:2110-24. [PMID: 33538583 DOI: 10.1021/acs.jmedchem.0c01726] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Mahameed M, Xue S, Stefanov BA, Hamri GC, Fussenegger M. Engineering a Rapid Insulin Release System Controlled By Oral Drug Administration. Adv Sci (Weinh) 2022;9:e2105619. [PMID: 35048556 DOI: 10.1002/advs.202105619] [Reference Citation Analysis]
10 Chartier M, Desgagné M, Sousbie M, Rumsby C, Chevillard L, Théroux L, Haroune L, Côté J, Longpré JM, Boudreault PL, Marsault É, Sarret P. Pharmacodynamic and pharmacokinetic profiles of a neurotensin receptor type 2 (NTS2) analgesic macrocyclic analog. Biomed Pharmacother 2021;141:111861. [PMID: 34229249 DOI: 10.1016/j.biopha.2021.111861] [Reference Citation Analysis]
11 Aierken A, Xie YK, Dong W, Apaer A, Lin JJ, Zhao Z, Yang S, Xu ZZ, Yang F. Rational Design of a Modality-Specific Inhibitor of TRPM8 Channel against Oxaliplatin-Induced Cold Allodynia. Adv Sci (Weinh) 2021;8:e2101717. [PMID: 34658162 DOI: 10.1002/advs.202101717] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
12 Akbarian M, Khani A, Eghbalpour S, Uversky VN. Bioactive Peptides: Synthesis, Sources, Applications, and Proposed Mechanisms of Action. Int J Mol Sci 2022;23:1445. [PMID: 35163367 DOI: 10.3390/ijms23031445] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
13 Gonzalez S, Dumitrascuta M, Eiselt E, Louis S, Kunze L, Blasiol A, Vivancos M, Previti S, Dewolf E, Martin C, Tourwé D, Cavelier F, Gendron L, Sarret P, Spetea M, Ballet S. Optimized Opioid-Neurotensin Multitarget Peptides: From Design to Structure-Activity Relationship Studies. J Med Chem 2020;63:12929-41. [PMID: 32902268 DOI: 10.1021/acs.jmedchem.0c01376] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
14 Wang H, Li X, Zhangsun D, Yu G, Su R, Luo S. The α9α10 Nicotinic Acetylcholine Receptor Antagonist αO-Conotoxin GeXIVA[1,2] Alleviates and Reverses Chemotherapy-Induced Neuropathic Pain. Mar Drugs 2019;17:E265. [PMID: 31060282 DOI: 10.3390/md17050265] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]